[go: up one dir, main page]

WO2005012360A3 - Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci - Google Patents

Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci Download PDF

Info

Publication number
WO2005012360A3
WO2005012360A3 PCT/EP2004/051568 EP2004051568W WO2005012360A3 WO 2005012360 A3 WO2005012360 A3 WO 2005012360A3 EP 2004051568 W EP2004051568 W EP 2004051568W WO 2005012360 A3 WO2005012360 A3 WO 2005012360A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding molecules
sars
coronavirus
molecules against
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/051568
Other languages
English (en)
Other versions
WO2005012360A2 (fr
Inventor
Meulen Jan Henrik Ter
Kruif Cornelis Adriaan De
Den Brink Edward Norbert Van
Jaap Goudsmit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP04766282.0A priority Critical patent/EP1644414B1/fr
Priority to NZ544821A priority patent/NZ544821A/en
Priority to CA2531684A priority patent/CA2531684C/fr
Priority to AU2004260884A priority patent/AU2004260884B2/en
Priority to KR1020067001386A priority patent/KR101206206B1/ko
Priority to CN2004800211505A priority patent/CN1826356B/zh
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Publication of WO2005012360A2 publication Critical patent/WO2005012360A2/fr
Publication of WO2005012360A3 publication Critical patent/WO2005012360A3/fr
Priority to US11/337,300 priority patent/US7696330B2/en
Anticipated expiration legal-status Critical
Priority to US12/590,973 priority patent/US20100172917A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)

Abstract

L'invention concerne des molécules de liaison qui se lient spécifiquement au coronavirus du syndrome respiratoire aigu sévère (SARS-CoV), des molécules d'acide nucléique codant pour les molécules de liaison, des compositions comprenant ces molécules et des procédés d'identification ou de production desdites molécules. Les molécules de liaison peuvent se lier spécifiquement au SARS-CoV et peuvent servir à diagnostiquer, à prévenir et/ou à traiter un trouble engendré par le SARS-CoV.
PCT/EP2004/051568 2003-07-22 2004-07-21 Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci Ceased WO2005012360A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
NZ544821A NZ544821A (en) 2003-07-22 2004-07-21 Binding molecules against SARS-Coronavirus and uses thereof
CA2531684A CA2531684C (fr) 2003-07-22 2004-07-21 Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci
AU2004260884A AU2004260884B2 (en) 2003-07-22 2004-07-21 Binding molecules against SARS-coronavirus and uses thereof
KR1020067001386A KR101206206B1 (ko) 2003-07-22 2004-07-21 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
CN2004800211505A CN1826356B (zh) 2003-07-22 2004-07-21 针对sars冠状病毒的结合分子及其应用
EP04766282.0A EP1644414B1 (fr) 2003-07-22 2004-07-21 Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci
US11/337,300 US7696330B2 (en) 2003-07-22 2006-01-20 Binding molecules against SARS-coronavirus and uses thereof
US12/590,973 US20100172917A1 (en) 2003-07-22 2009-11-16 Binding molecules against SARS-coronavirus and uses thereof

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
EPPCT/EP03/50328 2003-07-22
EP0350328 2003-07-22
EPPCT/EP03/50391 2003-09-01
EP0350391 2003-09-01
EPPCT/EP03/50723 2003-10-16
EP0350723 2003-10-16
EPPCT/EP03/50883 2003-11-24
EP0350883 2003-11-24
EPPCT/EP03/50943 2003-12-04
EP0350943 2003-12-04
EPPCT/EP04/050067 2004-02-02
EP2004050067 2004-02-02
EP2004050127 2004-02-13
EPPCT/EP04/050127 2004-02-13
EP2004050334 2004-03-19
EPPCT/EP04/050334 2004-03-19
EPPCT/EP04/050464 2004-04-07
EP2004050464 2004-04-07
EPPCT/EP04/050516 2004-04-14
EP2004050516 2004-04-14
EPPCT/EP04/050643 2004-04-29
EP2004050643 2004-04-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/337,300 Continuation US7696330B2 (en) 2003-07-22 2006-01-20 Binding molecules against SARS-coronavirus and uses thereof

Publications (2)

Publication Number Publication Date
WO2005012360A2 WO2005012360A2 (fr) 2005-02-10
WO2005012360A3 true WO2005012360A3 (fr) 2005-09-29

Family

ID=34120228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/051568 Ceased WO2005012360A2 (fr) 2003-07-22 2004-07-21 Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci

Country Status (6)

Country Link
US (2) US7696330B2 (fr)
KR (1) KR101206206B1 (fr)
AU (1) AU2004260884B2 (fr)
CA (1) CA2531684C (fr)
SG (1) SG128680A1 (fr)
WO (1) WO2005012360A2 (fr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
CA2490280A1 (fr) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Anticorps qui se lient specifiquement a reg iv
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2872136C (fr) 2002-07-18 2017-06-20 Merus B.V. Production par recombinaison de melanges d'anticorps
SG156535A1 (en) 2002-12-17 2009-11-26 Crucell Holland Bv Recombinant viral-based malaria vaccines
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (fr) 2003-05-30 2013-02-27 Merus B.V. Bibliothèque de fragments fab pour préparer un mélange d'anticorps
CA2531684C (fr) 2003-07-22 2014-03-11 Crucell Holland B.V. Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci
EP1660016A4 (fr) * 2003-08-04 2008-04-16 Univ Massachusetts Acides nucleiques, proteines, vaccins contre le sras et leurs utilisations
NZ580607A (en) * 2004-05-27 2011-05-27 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
WO2005118813A2 (fr) * 2004-06-04 2005-12-15 Institut Pasteur Acides nucleiques, polypeptides, methodes d'expression, et compositions immunogenes associees a la proteine spike du coronavirus sras
WO2006040322A1 (fr) * 2004-10-12 2006-04-20 Crucell Holland B.V. Molecules de liaison destinees au traitement et a la detection du cancer
NZ583291A (en) * 2004-10-14 2011-06-30 Glaxosmithkline Biolog Sa Malaria prime/boost vaccines using adenoviral vectors and adjuvated proteins
ATE550037T1 (de) 2004-11-11 2012-04-15 Crucell Holland Bv Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen
CA2608058C (fr) 2005-05-12 2013-09-10 Crucell Holland B.V. Molecules de liaison specifiques de cellule hote capables de neutraliser des virus et leurs utilisations
US7888102B2 (en) 2005-07-22 2011-02-15 Crucell Holland B.V. Cell line for producing coronaviruses
EP1857116A1 (fr) * 2006-05-19 2007-11-21 Novoplant GmbH Polypeptides de liaison d'antigènes contre la glycoprotéine de spicule (S2) du virus corona bovin
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
AU2007293662B2 (en) * 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN104004094B (zh) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
CA2728004C (fr) * 2008-06-25 2022-05-24 Esbatech, An Alcon Biomedical Research Unit Llc Humanisation d'anticorps de lapins au moyen d'une infrastructure d'anticorps universelle
WO2010129033A2 (fr) * 2009-04-29 2010-11-11 Calmune Corporation Anticorps modifiés pour immunothérapie passive
KR20100127948A (ko) * 2009-05-27 2010-12-07 한국전자통신연구원 Ｓａｒｓ 코로나바이러스의 검출 및 억제용 펩타이드 화합물 및 그의 응용
AU2011268072C1 (en) * 2010-06-17 2017-10-19 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
ES2378976B1 (es) * 2010-09-21 2013-05-06 Fundación Centro Nacional De Investigaciones Oncológicas (Cnio) Anticuerpo contra ephrin b2 y su uso.
AU2011326564A1 (en) 2010-11-10 2013-05-09 Genentech, Inc. Methods and compositions for neural disease immunotherapy
CA2791109C (fr) 2011-09-26 2021-02-16 Merus B.V. Generation de molecules de liaison
AU2012347878B2 (en) 2011-12-05 2018-05-10 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
KR102269650B1 (ko) 2012-04-20 2021-06-28 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
MX387277B (es) 2013-03-14 2025-03-12 Contrafect Corp Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CN106795216B (zh) 2014-02-04 2021-04-20 抗非特公司 可用于被动流感免疫的抗体及其组合物、组合和使用方法
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CN107074965B (zh) 2014-06-26 2021-08-03 扬森疫苗与预防公司 特异性结合微管相关蛋白tau的抗体和抗原结合片段
JP6859259B2 (ja) 2014-11-19 2021-04-14 ジェネンテック， インコーポレイテッド ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
US11008403B2 (en) 2014-11-19 2021-05-18 Genentech, Inc. Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
WO2016164408A1 (fr) * 2015-04-06 2016-10-13 The General Hospital Corporation Réactifs anti-cspg4 et méthodes de traitement du cancer
SG11201807596YA (en) 2016-03-08 2018-10-30 Janssen Biotech Inc Gitr antibodies, methods, and uses
EA037973B1 (ru) * 2016-10-12 2021-06-18 Янссен Байотек, Инк. Антитела к gitr, способы и применение
US11617753B2 (en) 2016-11-10 2023-04-04 Oyagen, Inc. Methods of treating and inhibiting Ebola virus infection
WO2019217455A1 (fr) 2018-05-07 2019-11-14 Genmab A/S Méthodes de traitement du cancer à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un conjugué anticorps anti-facteur tissulaire-médicament
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
EA202191242A1 (ru) * 2018-12-31 2021-11-25 Мерус Н.В. Усеченные поливалентные мультимеры
JP2022530442A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド アントラサイクリン抗体薬物複合体およびその使用
EP3778875A1 (fr) 2019-08-14 2021-02-17 MaxiVax SA Lignées de cellules myoblastes immortalisées et leurs utilisations
CA3158491A1 (fr) * 2019-10-24 2021-04-29 Novago Therapeutics Ag Nouveaux anticorps anti-nogo-a
TW202204380A (zh) * 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
WO2021158248A1 (fr) * 2020-02-04 2021-08-12 Oyagen, Inc. Méthodes de traitement d'infections à coronavirus
CA3166949A1 (fr) * 2020-02-11 2021-08-19 James E. Crowe Anticorps monoclonaux humains diriges contre le coronavirus 2 du syndrome respiratoire aigu severe (sars-cov-2)
KR20220164465A (ko) 2020-02-26 2022-12-13 비르 바이오테크놀로지, 인코포레이티드 Sars-cov-2에 대한 항체 및 이의 사용 방법
CN113321714B (zh) * 2020-02-28 2022-12-09 深圳市亚辉龙生物科技股份有限公司 SARS-CoV-2的重组N蛋白及其制备与纯化方法
IL296224A (en) * 2020-03-09 2022-11-01 Abcellera Biologics Inc Anti-coronavirus antibodies and methods of use
WO2021198706A2 (fr) * 2020-04-01 2021-10-07 Diosynvax Ltd Vaccins contre le coronavirus
WO2021202912A1 (fr) * 2020-04-01 2021-10-07 Washington University Compositions pour le traitement d'infections respiratoires virales et méthodes d'utilisation associées
WO2021205083A2 (fr) 2020-04-11 2021-10-14 Finindsutria Srl Composition pour la prévention ou le traitement du covid-19
CA3175523A1 (fr) 2020-04-13 2021-10-21 Antti Virtanen Procedes, complexes et kits pour detecter ou determiner une quantite d'un anticorps a .beta.-coronavirus dans un echantillon
JP2023521837A (ja) * 2020-04-14 2023-05-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 大きな配列の汎コロナウイルスワクチン組成物
CN115811986A (zh) 2020-04-22 2023-03-17 生物技术欧洲股份公司 冠状病毒疫苗
WO2021214467A1 (fr) * 2020-04-23 2021-10-28 Cellbio Amélioration d'un outil de diagnostic comprenant une molécule de liaison à un agent pathogène
IL297701A (en) * 2020-04-27 2022-12-01 Twist Bioscience Corp Variable libraries of nucleic acids for the coronavirus
SG11202112792WA (en) * 2020-04-28 2021-12-30 Univ Rockefeller Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
EP4149538A1 (fr) 2020-05-11 2023-03-22 Janssen Pharmaceuticals, Inc. Vaccins contre le sars-cov-2
US20230257726A1 (en) * 2020-05-11 2023-08-17 Chan Zuckerberg Biohub, Inc. Ace2 compositions and methods
US11066712B1 (en) * 2020-05-18 2021-07-20 Bret T. Barnhizer Rapid viral assay
WO2021236869A2 (fr) * 2020-05-20 2021-11-25 The Johns Hopkins University Procédés de détection de virus
WO2021237124A1 (fr) * 2020-05-22 2021-11-25 Icahn School Of Medicine At Mount Sinai Particules de vsv-delta g pseudotypé de protéine de spicule de sars-cov-2 et leurs utilisations
US20230212267A1 (en) * 2020-06-09 2023-07-06 David Weiner Dna antibody constructs for use against sars-cov-2
JP2023534923A (ja) 2020-07-06 2023-08-15 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子
CA3183373A1 (fr) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Molecules de liaison a l'antigene ciblant le sars-cov-2
US20230279078A1 (en) * 2020-07-20 2023-09-07 Astrazeneca Uk Limited Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same
KR20220012826A (ko) * 2020-07-23 2022-02-04 (주)셀트리온 사스-코로나바이러스-2 스파이크 단백질의 에피토프에 결합하는 사스-코로나바이러스-2 중화 결합 분자
WO2022026475A2 (fr) * 2020-07-27 2022-02-03 Igm Biosciences, Inc. Molécules de liaison à un coronavirus multimériques et leurs utilisations
WO2022031804A1 (fr) 2020-08-04 2022-02-10 Abbott Laboratories Méthodes et kits améliorés pour détecter une protéine sars-cov-2 dans un échantillon
CN116194477A (zh) * 2020-08-06 2023-05-30 生物技术欧洲股份公司 冠状病毒s蛋白的结合剂
WO2022035197A1 (fr) * 2020-08-11 2022-02-17 (주)셀트리온 Formulation pharmaceutique stable
WO2022032368A1 (fr) * 2020-08-14 2022-02-17 Instituto Butantan Procédé de production d'un antigène, correspondant aux virus sars-cov-2, inactivé, antigène, correspondant aux virus sars-cov-2, inactivé, composition antigénique, kits et utilisations correspondantes
EP4204446A1 (fr) 2020-08-26 2023-07-05 Flagship Pioneering Innovations VI, LLC Molécules de liaison à l'antigène ciblant le sars-cov-2
US20230364220A1 (en) * 2020-10-13 2023-11-16 The Government of the United States, as Respresented by the Secretary of the Army SAR-COV-2 DNA Vaccine and Method of Administering Thereof
US12171824B2 (en) * 2020-11-06 2024-12-24 Cho Pharma, Inc. Immune composition comprising antigen and glycoengineered antibody thereof
CA3198795A1 (fr) 2020-11-18 2022-05-27 Jeffrey Becker Formulations salines de composes pharmaceutiques a base d'agents complexants
WO2022112392A1 (fr) 2020-11-26 2022-06-02 Memo Therapeutics Ag Molécules d'anticorps anti-sars-cov-2
KR102412231B1 (ko) * 2020-12-01 2022-06-27 부산대학교 산학협력단 코로나바이러스과 유래 스파이크 단백질과 ace2의 결합 표적 fret 바이오센서 및 이의 용도
TWI790518B (zh) * 2020-12-25 2023-01-21 國立陽明交通大學 病毒收集基體
JP2024505636A (ja) * 2021-01-15 2024-02-07 ザ ロックフェラー ユニバーシティー 抗ｓａｒｓ－ｃｏｖ－２中和抗体
CN113150130B (zh) * 2021-01-31 2022-10-18 中南大学湘雅医院 新型冠状病毒单克隆抗体及其应用
EP4147716A1 (fr) * 2021-09-10 2023-03-15 Samatva Research Corporation Composant anti-virus immobilisé dans une matrice
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CA3250276A1 (fr) 2022-05-06 2023-11-09 Generate Biomedicines Inc Molécules de liaison à l'antigène ciblant le sars-cov-2
WO2024002985A1 (fr) 2022-06-26 2024-01-04 BioNTech SE Vaccin contre le coronavirus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101621A1 (fr) * 2003-05-13 2004-11-25 Jason Medical Group(Far East)Limited Immunoglobuline (ig) y specifique contre le syndrome respiratoire aigu severe (sras), technique de preparation de celle-ci et combinaison de preparations contenant celle-ci

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US20050186575A1 (en) * 2001-05-17 2005-08-25 Rottier Petrus J.M. Corona-virus-like particles comprising functionally deleted genomes
US7556957B2 (en) * 2001-05-17 2009-07-07 Stichting Voor De Technische Wetenschappen Coronavirus-like particles comprising functionally deleted genomes
ATE473274T1 (de) * 2001-05-17 2010-07-15 Univ Utrecht Coronavirus-ähnliche partikel enthaltende funktionell deletierte genome
FR2828405B1 (fr) 2001-08-09 2005-06-24 Virbac Sa Vaccin anti-coronavirus
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1633775A2 (fr) * 2003-06-13 2006-03-15 Crucell Holland B.V. Peptides antigeniques de coronavirus de sars, et utilisations
WO2005012337A2 (fr) 2003-07-15 2005-02-10 Crucell Holland B.V. Peptides antigeniques du coronavirus du syndrome respiratoire aigu severe et applications de ceux-ci
EP1646645A1 (fr) * 2003-07-21 2006-04-19 Crucell Holland B.V. Peptides antigeniques du coronavirus du sras et utilisations associees
CA2531684C (fr) * 2003-07-22 2014-03-11 Crucell Holland B.V. Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci
WO2005047459A2 (fr) * 2003-08-04 2005-05-26 University Of Massachusetts Acides nucleiques du sars, proteines, anticorps et utilisations associees
ATE500320T1 (de) * 2003-08-18 2011-03-15 Amsterdam Inst Of Viral Genomics B V Coronavirus, nukleinsäure, protein, verfahren zur erzeugung der impfstoffe, medikamente und diagnostika
NZ580607A (en) * 2004-05-27 2011-05-27 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
WO2006040322A1 (fr) * 2004-10-12 2006-04-20 Crucell Holland B.V. Molecules de liaison destinees au traitement et a la detection du cancer
NZ583291A (en) * 2004-10-14 2011-06-30 Glaxosmithkline Biolog Sa Malaria prime/boost vaccines using adenoviral vectors and adjuvated proteins
ATE550037T1 (de) * 2004-11-11 2012-04-15 Crucell Holland Bv Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen
EP1893645A1 (fr) * 2005-06-23 2008-03-05 Crucell Holland B.V. Optimisation d anticorps anti virus nil ouest
US7888102B2 (en) * 2005-07-22 2011-02-15 Crucell Holland B.V. Cell line for producing coronaviruses
AU2006290736B2 (en) * 2005-09-15 2011-09-15 Crucell Holland B.V. Method for preparing immunoglobulin libraries
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
AU2007293662B2 (en) * 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101621A1 (fr) * 2003-05-13 2004-11-25 Jason Medical Group(Far East)Limited Immunoglobuline (ig) y specifique contre le syndrome respiratoire aigu severe (sras), technique de preparation de celle-ci et combinaison de preparations contenant celle-ci

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200478, Derwent World Patents Index; Class B04, AN 2004-083758, XP002339683 *
KSIAZEK THOMAS G ET AL: "A novel coronavirus associated with severe acute respiratory syndrome.", THE NEW ENGLAND JOURNAL OF MEDICINE. 15 MAY 2003, vol. 348, no. 20, 15 May 2003 (2003-05-15), pages 1953 - 1966, XP002339648, ISSN: 1533-4406 *
LIN YING ET AL: "Identification of an epitope of SARS-coronavirus nucleocapsid protein.", CELL RESEARCH. JUN 2003, vol. 13, no. 3, June 2003 (2003-06-01), pages 141 - 145, XP002339647, ISSN: 1001-0602 *

Also Published As

Publication number Publication date
AU2004260884A1 (en) 2005-02-10
KR20060120568A (ko) 2006-11-27
US20100172917A1 (en) 2010-07-08
CA2531684A1 (fr) 2005-02-10
AU2004260884B2 (en) 2009-11-19
KR101206206B1 (ko) 2012-11-29
WO2005012360A2 (fr) 2005-02-10
US20060121580A1 (en) 2006-06-08
CA2531684C (fr) 2014-03-11
US7696330B2 (en) 2010-04-13
SG128680A1 (en) 2007-01-30

Similar Documents

Publication Publication Date Title
WO2005012360A3 (fr) Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci
WO2005118644A3 (fr) Molecules de liaison pouvant neutraliser le virus de la rage et utilisation
WO2007141274A3 (fr) Molécules de liaison humaines présentant une activité bactéricide contre les staphylocoques et leurs utilisations
WO2005063819A3 (fr) Molecule de liaison humaine contre cd1a
WO2007141278A3 (fr) molécules de liaison humaines à activité bactéricide contre les entérococci et leurs emplois
WO2005059096A3 (fr) Methodes pour une production haute fidelite de molecules d'acide nucleique long associee a un controle d'erreurs
WO2007062160A3 (fr) Procedes et compositions de sequençage d'un acide nucleique
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2007095316A3 (fr) Compositions et procédés pour formulations à base d'oligonucléotides
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
WO2005000894A3 (fr) Molecules de liaison pour traiter les malignites de cellules myeloides
WO2005017205A3 (fr) Cartographie de l'acide nucleique par une analyse lineaire
WO2005047471A3 (fr) Procede a efficacite amelioree du systeme fret
WO2005087951A3 (fr) Reactifs, procedes et kits utilise dans la desactivation d'acides nucleiques
WO2007144057A3 (fr) Carbone antimicrobien
WO2007134350A8 (fr) Utilisation d'un anticorps
WO2005079396A3 (fr) Complexes de o,o'-amidomalonate and n,o-amidomalonate platine
WO2007028151A3 (fr) Dispositifs chirurgicaux et methodes associees
WO2004074433A3 (fr) Polypeptides rag, acides nucleiques et utilisation
WO2005000870A3 (fr) Peptides ny-eso-1 isoles se liant a des molecules hla de classe ii et leurs utilisations
WO2004067569A8 (fr) Molecules de liaison humaines d'internalisation dirigees contre cd72
WO2005077397A3 (fr) Procedes et compositions pour le traitement de maladies vasculaires
WO2005009361A3 (fr) Methode de traitement a l'argatroban pour des patients souffrant de thrombocytopenie induite par l'heparine
EA201200182A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
WO2006043060A3 (fr) Proteine contenant le domaine mam

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480021150.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004260884

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2531684

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004766282

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 243/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 544821

Country of ref document: NZ

Ref document number: 11337300

Country of ref document: US

Ref document number: 1020067001386

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2004260884

Country of ref document: AU

Date of ref document: 20040721

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004260884

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004766282

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 11337300

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020067001386

Country of ref document: KR